In March 2020, the FDA temporarily postponed all routine domestic and foreign surveillance facility inspections. Only mission-critical inspections continued, when possible. By restricting site visits during the COVID-19 public health emergency limited the spread of the virus and maintained a healthy workforce, both for food manufacturers and the FDA. Although mission-critical inspections continued and temporary alternative tools were used to assess many facilities remotely, the pandemic halted many onsite inspections and created a significant backlog for FDA. This means for some facilities, it’s been over two years since the last FDA inspection.
Are you audit-ready?
With COVID vaccinations and boosters now available and as the pandemic wanes, the FDA has been working to reestablish onsite inspections and “transition to standard operations,” with FDA inspectors conducting surveillance domestic inspections. They’ve also suggested that some remote tools may continue to be utilized, creating efficiencies for the agency. As a result, it will be important for manufacturers subject to FDA’s oversight to be prepared.
Watch this on-demand with AIB International’s Global Manager for Food Defense and Food Safety Modernization Act, Earl Arnold, for guidance on how to achieve success with upcoming onsite inspections. Learn more about the latest developments and how to implement them within your team and facility.
Watch & learn:
In this on-demand webinar, you’ll discover:
- How the FDA is prioritizing inspections to address the backlog created by the pandemic.
- What may trigger a “for cause” inspection of your facility.
- What inspection components may continue to be conducted remotely.
- How to prepare your facility and your team for an onsite FDA Inspection.